Skip to content
Clinical Trials – home
RomaniaBack to Romania

Clinical trials in Bucharest – page 46

660 clinical trials in Bucharest, Romania across 19 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

RomaniaOur site in RomaniaStudii.Clinice.ro(opens in a new tab)
Bucharest at a glance
660
clinical trials
  • Research sites19
Type of trial
Recruitment status
Quick filters

660 trials in Bucharest

Open in trial search

Study of Secukinumab for Maintaining Remission in Patients with Non-Radiographic Axial Spondyloarthritis

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Secukinumab
  • Sponsor:Novartis Pharma AG

Study on Tiragolumab and Atezolizumab for Patients with Resected Stage IIB-IIIB Non-Small Cell Lung Cancer After Chemotherapy

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Study on Vudalimab or Pembrolizumab with Chemotherapy for Advanced Non-small Cell Lung Cancer Patients

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Xencor Inc.

Petit mal epilepsy+1

Not recruiting

Study of brivaracetam as a treatment for childhood and juvenile absence epilepsy in patients aged 2-25 years

Registered drug
Countries:RomaniaRomania
  • Participants:0–17 years · 18–64 years
  • Substances:Brivaracetam
  • Sponsor:UCB Biopharma

Rheumatoid arthritis

Not recruiting

Study on Monitoring Adalimumab for Maintaining Disease Control in Adults with Rheumatoid Arthritis

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years
  • Substances:Adalimumab
  • Sponsor:Diakonhjemmet Sykehus AS

Study of mRNA-4157 and Pembrolizumab for Patients with Resectable Locally Advanced Cutaneous Squamous Cell Carcinoma

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:MRNA-4157
  • Sponsor:Merck Sharp & Dohme LLC

Study Comparing Pirtobrutinib to Bendamustine and Rituximab for Untreated Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Pirtobrutinib
  • Sponsor:Loxo Oncology Inc.

Study of Tarlatamab for Patients with Limited-Stage Small-Cell Lung Cancer After Chemoradiotherapy

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Argipressin
  • Sponsor:Amgen Inc.

Bladder cancer

Not recruiting

Study Comparing Chemotherapy Alone to Chemotherapy with Nivolumab or Nivolumab and BMS-986205 for Patients with Muscle-Invasive Bladder Cancer

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study of Trastuzumab Deruxtecan for Patients with HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer After Trastuzumab Treatment

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Paclitaxel
  • Sponsor:Daiichi Sankyo Inc.
Countries:RomaniaRomania
  • Participants:18–64 years
  • Substances:AB-729
  • Sponsor:Arbutus Biopharma Inc.

Study of Enpatoran in Adults with Systemic Lupus Erythematosus (SLE) and Cutaneous Lupus Erythematosus (CLE)

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Enpatoran
  • Sponsor:Merck Healthcare KGaA

Other cities in Romania

The busiest research cities in the country

All 65 cities in Romania

Clinical research in Bucharest

What the registry says about research in the country

01 Cardiovascular Diseases

Clinical trial activity in Bucuresti includes a strong focus on cardiovascular diseases, with studies targeting atherosclerotic risk and event prevention in high-risk patients.

  • Atherosclerotic cardiovascular disease
  • Primary prevention of ASCVD
  • Risk reduction for major cardiovascular events

These trials are mainly designed to evaluate new approaches that may lower the chance of heart attacks, strokes, and other serious vascular complications.

02 Nervous System Diseases

The nervous system diseases portfolio covers conditions affecting cognition, movement, and headache disorders, reflecting a broad interest in neurological care and symptom control.

  • Agitation associated with Alzheimer’s disease
  • Migraine
  • Episodic migraine

Research here is focused on testing treatments that may improve daily functioning, reduce symptoms, and support long-term management in both adults and pediatric patients.

03 Mental Disorders

Trials in mental disorders are examining new options for people living with schizophrenia, especially those who do not respond well to standard antipsychotic treatment.

  • Schizophrenia
  • Adjunctive symptom management
  • Treatment response in difficult-to-manage psychiatric illness

The overall aim is to better control symptoms and improve treatment effectiveness for patients with ongoing psychiatric needs.

04 Respiratory Tract Diseases

In the area of respiratory tract diseases, studies are centered on moderate-to-severe uncontrolled asthma, with attention on therapies that may offer better symptom control.

  • Moderate-to-severe uncontrolled asthma
  • Symptom relief and disease control
  • Safety and effectiveness of new asthma treatments

These trials are exploring whether investigational therapies can help patients breathe more easily and reduce the burden of persistent asthma.

05 Nutritional and Metabolic Diseases

Research in nutritional and metabolic diseases includes studies on obesity and overweight, as well as related joint problems that often accompany excess body weight.

  • Obesity
  • Overweight
  • Knee osteoarthritis

The goal is to assess therapies that may support weight management and improve associated health outcomes, including joint pain and mobility.

06 Neoplasms

Oncology research in Bucuresti includes trials for limited-stage small cell lung cancer after chemoradiotherapy, with a focus on consolidation treatment strategies.

  • Limited-stage small cell lung cancer
  • Post-chemoradiotherapy disease control
  • Treatment effectiveness in lung cancer

These studies are evaluating whether new immunotherapy combinations can help maintain remission and improve survival outcomes.

07 Neurodegenerative and Psychiatric Symptom Research

Some trials bring together neurology and psychiatry by studying agitation in Alzheimer’s disease, an important symptom that can affect patients and caregivers alike.

  • Agitation associated with Alzheimer’s disease
  • Behavioral symptom management
  • Long-term safety and tolerability

The research is intended to find better ways to manage distressing behavioral symptoms while supporting longer-term treatment use.

08 Inflammation and Renal-Related Research

Another active area involves patients with ESKD undergoing dialysis, where studies are exploring inflammatory markers linked to cardiovascular risk.

  • End-stage kidney disease
  • Dialysis-associated inflammation
  • Reduction of high-sensitivity C-reactive protein

These trials aim to better understand whether new therapies can help reduce inflammation and potentially improve overall health outcomes in this high-risk group.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.